Follow this preprint
Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273
Veronica Urdaneta, Daina B. Esposito, Priyadarshani Dharia, Margot Stam Moraga, Kate Anteyi, Titi Oduyebo-Omotosho, Melissa Rossi, Paul Burton, José M. Vega, Rachel Dawson, Walter Straus
doi: https://doi.org/10.1101/2023.07.13.23291675
Now published in Open Forum Infectious Diseases doi: 10.1093/ofid/ofae067
Veronica Urdaneta
1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, MPHDaina B. Esposito
2Medical Affairs, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MPH, PhDPriyadarshani Dharia
2Medical Affairs, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, MPH, PhDMargot Stam Moraga
1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MSc, MPHKate Anteyi
1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, MPH, MBATiti Oduyebo-Omotosho
1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, MPHMelissa Rossi
1Clinical Safety and Risk Management, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MPHPaul Burton
2Medical Affairs, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
3Clinical Safety and Pharmacovigilance, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, PhDJosé M. Vega
3Clinical Safety and Pharmacovigilance, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MDRachel Dawson
2Medical Affairs, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
DO, MPHWalter Straus
3Clinical Safety and Pharmacovigilance, Moderna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
MD, MPH
Posted July 16, 2023.
Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273
Veronica Urdaneta, Daina B. Esposito, Priyadarshani Dharia, Margot Stam Moraga, Kate Anteyi, Titi Oduyebo-Omotosho, Melissa Rossi, Paul Burton, José M. Vega, Rachel Dawson, Walter Straus
medRxiv 2023.07.13.23291675; doi: https://doi.org/10.1101/2023.07.13.23291675
Now published in Open Forum Infectious Diseases doi: 10.1093/ofid/ofae067
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (410)
- Allergy and Immunology (725)
- Anesthesia (214)
- Cardiovascular Medicine (3085)
- Dermatology (260)
- Emergency Medicine (462)
- Epidemiology (13014)
- Forensic Medicine (13)
- Gastroenterology (860)
- Genetic and Genomic Medicine (4833)
- Geriatric Medicine (445)
- Health Economics (750)
- Health Informatics (3054)
- Health Policy (1101)
- Hematology (407)
- HIV/AIDS (956)
- Medical Education (453)
- Medical Ethics (119)
- Nephrology (499)
- Neurology (4602)
- Nursing (244)
- Nutrition (683)
- Oncology (2384)
- Ophthalmology (673)
- Orthopedics (268)
- Otolaryngology (333)
- Pain Medicine (300)
- Palliative Medicine (87)
- Pathology (514)
- Pediatrics (1238)
- Primary Care Research (519)
- Public and Global Health (7186)
- Radiology and Imaging (1601)
- Respiratory Medicine (943)
- Rheumatology (459)
- Sports Medicine (403)
- Surgery (509)
- Toxicology (65)
- Transplantation (220)
- Urology (188)